Compare PNNT & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNNT | OBIO |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.4M | 253.9M |
| IPO Year | 2007 | 2020 |
| Metric | PNNT | OBIO |
|---|---|---|
| Price | $3.75 | $4.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $5.75 | ★ $14.25 |
| AVG Volume (30 Days) | ★ 527.4K | 306.4K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 20.87% | N/A |
| EPS Growth | N/A | ★ 33.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,482,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.43 |
| P/E Ratio | $13.14 | ★ N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $3.19 | $2.20 |
| 52 Week High | $7.06 | $5.78 |
| Indicator | PNNT | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 55.25 | 50.11 |
| Support Level | $3.61 | $3.83 |
| Resistance Level | $3.89 | $4.82 |
| Average True Range (ATR) | 0.10 | 0.33 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 52.94 | 29.93 |
Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.